AI Daily: OpenAI said to forecast revenue topping $125B in 2029

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly:

REVENUE FORECAST: For two years, ChatGPT has been OpenAI’s cash cow, but by the end of the decade, the company has told some potential and current investors it expects combined sales from agents and other new products to exceed its popular chatbot, lifting total sales to $125B in 2029 and $174B the next year, according to documents seen by The Information. The projections, which would propel the 10-year-old startup’s sales toward the level of Nvidia (NVDA) or Meta Platforms (META) today, reflect rapid revenue gains from agents, or AI software that can take actions on behalf of customers, as well as other new products, The Information’s Sri Muppidi reports. These include those tied to “free user monetization,” likely meaning money made from OpenAI’s nonpaying users. 

GOOGLE CHROME: Nick Turley, the CEO of OpenAI’s ChatGPT, says the company would be interested in buying Google’s (GOOGL) Chrome browser if a federal court orders it to be spun off, Leah Nylen, Shirin Ghaffary, and Davey Alba of Bloomberg report. Turley testified that having Chrome more deeply integrated into Microsoft (MSFT)-backed OpenAI would allow for a better product and a more seamless user experience. The Justice Department is looking to force Google to divest Chrome, among other remedies, to prevent the company from monopolizing the online search market. 

COLLABORATION: Tempus AI (TEM) announced multi-year, strategic collaborations with AstraZeneca (AZN) and Pathos AI, in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Tempus’ de-identified oncology data will be used to build the foundation model. Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care. 

The agreement includes $200M in data licensing and model development fees to Tempus. The agreement with AstraZeneca expands on the strategic partnership between the two companies announced in 2021 and aims to leverage Tempus’ AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale.